' 
SCIENTIFIC SCORE
Moderately Effective
Based on 8 Researches
8.6
USERS' SCORE
Good
Based on 1 Review
8.5
Supplement Facts
Serving Size: 1 tbsp (15 ml)
Amount Per Serving
%DV
Calories
120
Total Fat
14 g
18%
Saturated Fat
2.5 g
13%
Polyunsaturated Fat
8 g
Monounsaturated Fat
2 g
Sodium
0 mg
0%
Total Carbohydrate
0 g
0%
Protein
0 g
Vitamin E
20 mg
130%
Top Medical Research Studies
9.5
Protein treatment for gout management
Albumin Corona-Coated Nanoscale Metal-Organic Framework for Enzyme-Mediated Cascade Metabolization of Uric Acid in Hyperuricemia.
Direct application to gout treatment
We explored the effectiveness of a novel treatment approach aimed at managing gout by focusing on protein treatments, specifically a form of uricase. This research highlights the development of an albumin corona-coated enzyme-loaded framework designed to sustainably control high uric acid levels without creating harmful byproducts.
What sets this method apart is its ability to protect the uricase enzymes while also minimizing the immune responses that typically accompany their use. In our analysis, we observed that this innovative combination drastically reduced the capture of uricase by immune cells, which can often trigger inflammation and other complications.
Animal studies demonstrated that this albumin-coated framework successfully lowered uric acid levels across different models of hyperuricemia. Importantly, it also extended the lifespan of the uricase in circulation, which may enhance its effectiveness over time. Moreover, we noted a significant drop in the production of antibodies that commonly arise from uricase treatments, indicating a potentially safer profile for this therapy.
Overall, our findings suggest that this albumin-coated nanoscale framework could represent a promising new direction for gout treatment, providing a safer alternative to traditional therapies that often lead to unwanted inflammatory responses.
What sets this method apart is its ability to protect the uricase enzymes while also minimizing the immune responses that typically accompany their use. In our analysis, we observed that this innovative combination drastically reduced the capture of uricase by immune cells, which can often trigger inflammation and other complications.
Animal studies demonstrated that this albumin-coated framework successfully lowered uric acid levels across different models of hyperuricemia. Importantly, it also extended the lifespan of the uricase in circulation, which may enhance its effectiveness over time. Moreover, we noted a significant drop in the production of antibodies that commonly arise from uricase treatments, indicating a potentially safer profile for this therapy.
Overall, our findings suggest that this albumin-coated nanoscale framework could represent a promising new direction for gout treatment, providing a safer alternative to traditional therapies that often lead to unwanted inflammatory responses.
Read More
9
Promising uricase-conjugate for gout
Nanourchin-like Uricase-Poly(-proline) Conjugate with Retained Enzymatic Activity, Mitigated Immunogenicity, and Sustained Efficacy Upon Repeated Administrations.
Effectively addresses gout treatment
We focused on the challenges of treating gout and hyperuricemia with the therapeutic enzyme uricase (UOx). Traditional treatments often struggle with issues like a short half-life and high immunogenicity, which can lead to reduced effectiveness over time.
In our exploration, we evaluated a new approach using a conjugate called UOx-PLP, which combines uricase with a polymer known as poly(-proline). This innovative combination was developed through a straightforward process, ensuring it maintained a high level of enzyme activity—about 82%—while also improving its stability against heat, freezing, and breakdown.
We observed that UOx-PLP created minimal immune response, unlike previous treatments that could lead to quicker clearance from the body due to the immune system recognizing them as foreign. Not only did UOx-PLP maintain its effectiveness after multiple doses, but it also proved resilient even in individuals who had previously been treated with another version, highlighting its potential as a better treatment option for gout patients. This promising research clearly demonstrates the potential of UOx-PLP to enhance the treatment landscape for gout.
In our exploration, we evaluated a new approach using a conjugate called UOx-PLP, which combines uricase with a polymer known as poly(-proline). This innovative combination was developed through a straightforward process, ensuring it maintained a high level of enzyme activity—about 82%—while also improving its stability against heat, freezing, and breakdown.
We observed that UOx-PLP created minimal immune response, unlike previous treatments that could lead to quicker clearance from the body due to the immune system recognizing them as foreign. Not only did UOx-PLP maintain its effectiveness after multiple doses, but it also proved resilient even in individuals who had previously been treated with another version, highlighting its potential as a better treatment option for gout patients. This promising research clearly demonstrates the potential of UOx-PLP to enhance the treatment landscape for gout.
Read More
9
Vitamin E as gout treatment
The inhibitory kinetics of vitamins B9, C, E, and D3 on bovine xanthine oxidase: Gout treatment.
Highly relevant to gout management
We explored the potential of vitamin E as a treatment for gout, a condition often triggered by high levels of uric acid in the body. Through both in silico and in vitro studies, we looked at how effectively vitamin E and other vitamins inhibit an enzyme called xanthine oxidase, which is linked to increased uric acid production.
Our findings are quite promising. The in vitro results showed that vitamin E acted as a potent inhibitor of xanthine oxidase with an IC50 value of 36.68 μM. This means it significantly reduced the activity of this enzyme compared to the control group. We discovered that vitamin E operates as a non-competitive inhibitor, which could potentially help manage uric acid levels effectively.
Overall, the study suggests that incorporating vitamin E into treatment plans may provide additional benefits for individuals grappling with hyperuricemia and gout. Not only could it enhance immunity, but it may also help reduce the side effects commonly associated with traditional medications used for this condition.
Our findings are quite promising. The in vitro results showed that vitamin E acted as a potent inhibitor of xanthine oxidase with an IC50 value of 36.68 μM. This means it significantly reduced the activity of this enzyme compared to the control group. We discovered that vitamin E operates as a non-competitive inhibitor, which could potentially help manage uric acid levels effectively.
Overall, the study suggests that incorporating vitamin E into treatment plans may provide additional benefits for individuals grappling with hyperuricemia and gout. Not only could it enhance immunity, but it may also help reduce the side effects commonly associated with traditional medications used for this condition.
Read More
Most Useful Reviews
8.8
Strength improvement
Good product. I use it on the area affected by arthritis and gout to massage. It works remarkably well. I feel more strength in my wrist and am able to lift items I previously struggled with. The smell isn't very pleasant, but it dissipates after a few minutes.
Read More
Medical Researches
SCIENTIFIC SCORE
Moderately Effective
Based on 8 Researches
8.6
9.5
Protein treatment for gout management
Albumin Corona-Coated Nanoscale Metal-Organic Framework for Enzyme-Mediated Cascade Metabolization of Uric Acid in Hyperuricemia.
Direct application to gout treatment
We explored the effectiveness of a novel treatment approach aimed at managing gout by focusing on protein treatments, specifically a form of uricase. This research highlights the development of an albumin corona-coated enzyme-loaded framework designed to sustainably control high uric acid levels without creating harmful byproducts.
What sets this method apart is its ability to protect the uricase enzymes while also minimizing the immune responses that typically accompany their use. In our analysis, we observed that this innovative combination drastically reduced the capture of uricase by immune cells, which can often trigger inflammation and other complications.
Animal studies demonstrated that this albumin-coated framework successfully lowered uric acid levels across different models of hyperuricemia. Importantly, it also extended the lifespan of the uricase in circulation, which may enhance its effectiveness over time. Moreover, we noted a significant drop in the production of antibodies that commonly arise from uricase treatments, indicating a potentially safer profile for this therapy.
Overall, our findings suggest that this albumin-coated nanoscale framework could represent a promising new direction for gout treatment, providing a safer alternative to traditional therapies that often lead to unwanted inflammatory responses.
What sets this method apart is its ability to protect the uricase enzymes while also minimizing the immune responses that typically accompany their use. In our analysis, we observed that this innovative combination drastically reduced the capture of uricase by immune cells, which can often trigger inflammation and other complications.
Animal studies demonstrated that this albumin-coated framework successfully lowered uric acid levels across different models of hyperuricemia. Importantly, it also extended the lifespan of the uricase in circulation, which may enhance its effectiveness over time. Moreover, we noted a significant drop in the production of antibodies that commonly arise from uricase treatments, indicating a potentially safer profile for this therapy.
Overall, our findings suggest that this albumin-coated nanoscale framework could represent a promising new direction for gout treatment, providing a safer alternative to traditional therapies that often lead to unwanted inflammatory responses.
Read More
9
Promising uricase-conjugate for gout
Nanourchin-like Uricase-Poly(-proline) Conjugate with Retained Enzymatic Activity, Mitigated Immunogenicity, and Sustained Efficacy Upon Repeated Administrations.
Effectively addresses gout treatment
We focused on the challenges of treating gout and hyperuricemia with the therapeutic enzyme uricase (UOx). Traditional treatments often struggle with issues like a short half-life and high immunogenicity, which can lead to reduced effectiveness over time.
In our exploration, we evaluated a new approach using a conjugate called UOx-PLP, which combines uricase with a polymer known as poly(-proline). This innovative combination was developed through a straightforward process, ensuring it maintained a high level of enzyme activity—about 82%—while also improving its stability against heat, freezing, and breakdown.
We observed that UOx-PLP created minimal immune response, unlike previous treatments that could lead to quicker clearance from the body due to the immune system recognizing them as foreign. Not only did UOx-PLP maintain its effectiveness after multiple doses, but it also proved resilient even in individuals who had previously been treated with another version, highlighting its potential as a better treatment option for gout patients. This promising research clearly demonstrates the potential of UOx-PLP to enhance the treatment landscape for gout.
In our exploration, we evaluated a new approach using a conjugate called UOx-PLP, which combines uricase with a polymer known as poly(-proline). This innovative combination was developed through a straightforward process, ensuring it maintained a high level of enzyme activity—about 82%—while also improving its stability against heat, freezing, and breakdown.
We observed that UOx-PLP created minimal immune response, unlike previous treatments that could lead to quicker clearance from the body due to the immune system recognizing them as foreign. Not only did UOx-PLP maintain its effectiveness after multiple doses, but it also proved resilient even in individuals who had previously been treated with another version, highlighting its potential as a better treatment option for gout patients. This promising research clearly demonstrates the potential of UOx-PLP to enhance the treatment landscape for gout.
Read More
9
Vitamin E as gout treatment
The inhibitory kinetics of vitamins B9, C, E, and D3 on bovine xanthine oxidase: Gout treatment.
Highly relevant to gout management
We explored the potential of vitamin E as a treatment for gout, a condition often triggered by high levels of uric acid in the body. Through both in silico and in vitro studies, we looked at how effectively vitamin E and other vitamins inhibit an enzyme called xanthine oxidase, which is linked to increased uric acid production.
Our findings are quite promising. The in vitro results showed that vitamin E acted as a potent inhibitor of xanthine oxidase with an IC50 value of 36.68 μM. This means it significantly reduced the activity of this enzyme compared to the control group. We discovered that vitamin E operates as a non-competitive inhibitor, which could potentially help manage uric acid levels effectively.
Overall, the study suggests that incorporating vitamin E into treatment plans may provide additional benefits for individuals grappling with hyperuricemia and gout. Not only could it enhance immunity, but it may also help reduce the side effects commonly associated with traditional medications used for this condition.
Our findings are quite promising. The in vitro results showed that vitamin E acted as a potent inhibitor of xanthine oxidase with an IC50 value of 36.68 μM. This means it significantly reduced the activity of this enzyme compared to the control group. We discovered that vitamin E operates as a non-competitive inhibitor, which could potentially help manage uric acid levels effectively.
Overall, the study suggests that incorporating vitamin E into treatment plans may provide additional benefits for individuals grappling with hyperuricemia and gout. Not only could it enhance immunity, but it may also help reduce the side effects commonly associated with traditional medications used for this condition.
Read More
9
Camellia japonica's potential in gout
Identification of the biologically active constituents of Camellia japonica leaf and anti-hyperuricemic effect in vitro and in vivo.
Moderate relevance to vitamin E
We explored the effects of Camellia japonica leaf extract, particularly focusing on its components like vitamin E, to understand its role in managing gout. Our study investigated the antioxidant properties and the ability of this extract to inhibit xanthine oxidase, an enzyme linked to elevated uric acid levels, which can contribute to gout.
Through a series of tests, including in vitro studies and trials on mice induced with hyperuricemia, we observed promising results. The extract showed strong antioxidant activity and effectively inhibited the xanthine oxidase enzyme, critical for controlling uric acid production.
However, while the extract may offer benefits related to hyperuricemia, we did not isolate the specific effects of vitamin E on gout. Thus, it's challenging to conclude how significant vitamin E's role is in this context. As such, further research is needed to determine whether vitamin E alone can directly influence gout symptoms or management.
Overall, the extract from Camellia japonica leaves demonstrates potential in gout treatment due to its complex makeup, but the precise impact of vitamin E remains unclear from this study.
Through a series of tests, including in vitro studies and trials on mice induced with hyperuricemia, we observed promising results. The extract showed strong antioxidant activity and effectively inhibited the xanthine oxidase enzyme, critical for controlling uric acid production.
However, while the extract may offer benefits related to hyperuricemia, we did not isolate the specific effects of vitamin E on gout. Thus, it's challenging to conclude how significant vitamin E's role is in this context. As such, further research is needed to determine whether vitamin E alone can directly influence gout symptoms or management.
Overall, the extract from Camellia japonica leaves demonstrates potential in gout treatment due to its complex makeup, but the precise impact of vitamin E remains unclear from this study.
Read More
8
DFV890 shows promise for gout
Discovery of DFV890, a Potent Sulfonimidamide-Containing NLRP3 Inflammasome Inhibitor.
Specific compound focus limits relevance.
Our focus was on examining DFV890, a newly discovered and powerful inhibitor that targets the NLRP3 inflammasome, which plays a significant role in inflammation, particularly in gout. This compound is derived from a revision of the sulfonyl urea core found in previous NLRP3 antagonists, specifically CRID3, leading to the development of a more effective sulfonimidamide series.
We discovered that the enantiomers of the sulfonimidamide series displayed consistently stronger effects than their sulfonyl urea counterparts. The design innovation continued with the replacement of a furan unit with a thiazole unit, resulting in DFV890. This compound was observed to effectively hinder IL-1β production in both THP-1 cells and primary human cells.
Additionally, DFV890 appears to impact several downstream effects of NLRP3 activation while also improving pharmacokinetic properties. This means it could provide a significantly lower expected dose for humans compared to the earlier CRID3 variant. The compound also showed effectiveness in an air pouch model of gout, aiming to address the inflammation tied to this painful condition.
Overall, our findings highlight DFV890's potential as a promising candidate for treating gout, particularly through its targeted approach in modulating inflammatory responses.
We discovered that the enantiomers of the sulfonimidamide series displayed consistently stronger effects than their sulfonyl urea counterparts. The design innovation continued with the replacement of a furan unit with a thiazole unit, resulting in DFV890. This compound was observed to effectively hinder IL-1β production in both THP-1 cells and primary human cells.
Additionally, DFV890 appears to impact several downstream effects of NLRP3 activation while also improving pharmacokinetic properties. This means it could provide a significantly lower expected dose for humans compared to the earlier CRID3 variant. The compound also showed effectiveness in an air pouch model of gout, aiming to address the inflammation tied to this painful condition.
Overall, our findings highlight DFV890's potential as a promising candidate for treating gout, particularly through its targeted approach in modulating inflammatory responses.
Read More
User Reviews
USERS' SCORE
Good
Based on 1 Review
8.5
8.8
Strength improvement
Good product. I use it on the area affected by arthritis and gout to massage. It works remarkably well. I feel more strength in my wrist and am able to lift items I previously struggled with. The smell isn't very pleasant, but it dissipates after a few minutes.
